Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, DiaMedica Therapeutics's Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 was $-29.08 Mil. Therefore, DiaMedica Therapeutics's EV-to-EBIT ratio for today is -4.09.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, DiaMedica Therapeutics's Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was $-29.04 Mil. Therefore, DiaMedica Therapeutics's EV-to-EBITDA ratio for today is -4.10.
DiaMedica Therapeutics Enterprise Value Historical Data
The historical data trend for DiaMedica Therapeutics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of DiaMedica Therapeutics's Enterprise Value
For the Biotechnology subindustry, DiaMedica Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Enterprise Value falls into.
DiaMedica Therapeutics Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
DiaMedica Therapeutics's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (NAS:DMAC) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
DiaMedica Therapeutics's current Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.08 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
DiaMedica Therapeutics's EV-to-EBITDA for today is:
DiaMedica Therapeutics's current Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.04 Mil.
DiaMedica Therapeutics's current Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
DiaMedica Therapeutics's current Enterprise Value is $119.02 Mil.
DiaMedica Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics Enterprise Value Related Terms
Thank you for viewing the detailed overview of DiaMedica Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DMAC has been successfully added to your 